SLCO1B1 and Hyperbilirubinemia: Interestingly, Zhang et al. [66] reported that serum bilirubin level is influenced by the SLCO1B1 diplotype, whilst an increase in the serum bilirubin level after low-dose RIF use did not depend on genetic background, suggesting that RIF administration may aggravate pre-existing hyperbilirubinemia and liver impairment but not to be their primary cause.